Considering that sorafenib is able to induce clinical response in about 30 % of HCC patients, it could be worth verifying the real frequency of BRAF mutations in this type of cancer, and whether a higher frequency of mutation is related to sorafenib response. This evidence concerns the gene BRAF and hepatocellular carcinoma.